Infervision deployed InferOperate Suite to visualize nodule–structure relationships and evaluate segment volumes for a minimally invasive S3 + S1+2c segmentectomy with lung-preserving surgical planning.

Infervision is a pioneering AI medical technology company, established in 2016, with a mission to advance multidisciplinary healthcare services through artificial intelligence. Supporting healthcare providers across three critical areas—disease screening/detection to diagnosis to patient treatment and management as well as research and development—Infervision empowers medical institutions to enhance operational efficiency and patient outcomes. Our comprehensive suite of AI-driven software addresses a broad spectrum of medical needs. From detecting cancers, infectious diseases, cardiovascular conditions, and cerebrovascular diseases to managing trauma and more, Infervision’s solutions are relied upon globally. With specialized modules for disease screening and diagnosis (InferRead®), interventional support and treatment (InferOperate®), patient health management (InferCare®), and medical education and research (InferScholar®, InferMatrix, InferEducate), Infervision is a trusted partner to hospitals, medical institutions, governments, healthcare professionals, and patients worldwide. We also actively engage in academic research, maintaining deep collaborations with leading institutions in radiology and medical technology. Our partnerships span over 1000 of the top hospitals across North America, Europe, and Asia, forming a sophisticated AI computing and precision healthcare intelligence system. These collaborations bridge the gap between medical data, technology, and real-world healthcare applications. This solidifies our position as a global leader in medical AI innovation and advancing the fields of medical imaging for diagnosis and treatments.

Founded 2016